REN and atrial fibrillation: Current evidence supports renin–angiotensin–aldosterone (RAAS) inhibition with angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB) or, potentially, mineralocorticoid receptor antagonists (MRA) as an upstream therapy for AF management [6–9].